Hangzhou Biotest Biotech Co Ltd - Asset Resilience Ratio

Latest as of March 2026: 0.56%

Hangzhou Biotest Biotech Co Ltd (688767) has an Asset Resilience Ratio of 0.56% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets

CN¥13.93 Million

≈ $2.04 Million USD Cash + Short-term Investments

Total Assets

CN¥2.49 Billion

≈ $363.78 Million USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2021–2025)

This chart shows how Hangzhou Biotest Biotech Co Ltd's Asset Resilience Ratio has changed over time. See 688767 financial flexibility score to measure the company's free cash flow as a share of total liabilities.

Liquid Assets Composition Over Time

This chart breaks down Hangzhou Biotest Biotech Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Hangzhou Biotest Biotech Co Ltd (688767) total market value.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	CN¥0.00	0%
Short-term Investments	CN¥13.93 Million	0.56%
Total Liquid Assets	CN¥13.93 Million	0.56%

Asset Resilience Insights

Limited Liquidity: Hangzhou Biotest Biotech Co Ltd maintains only 0.56% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company has significant short-term investments, indicating active treasury management.

Hangzhou Biotest Biotech Co Ltd Industry Peers by Asset Resilience Ratio

Compare Hangzhou Biotest Biotech Co Ltd's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
argenx NV ADR NASDAQ:ARGX	Biotechnology	10.93%
Abivax SA PA:ABVX	Biotechnology	2.34%
Genscript Biotech Corporation F:G51	Biotechnology	13.79%
Zealand Pharma A/S CO:ZEAL	Biotechnology	63.98%
ZAI LAB LTD0000006 F:1ZLB	Biotechnology	0.91%
Jiangxi Fushine Pharmaceutical Co Ltd SHE:300497	Biotechnology	0.02%
Galapagos N.V. AS:GLPG	Biotechnology	86.45%
Chengdu Easton Biopharmaceuticals Co Ltd SHG:688513	Biotechnology	34.30%

Annual Asset Resilience Ratio for Hangzhou Biotest Biotech Co Ltd (2021–2025)

The table below shows the annual Asset Resilience Ratio data for Hangzhou Biotest Biotech Co Ltd.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-12-31	0.54%	CN¥13.76 Million ≈ $2.01 Million	CN¥2.54 Billion ≈ $371.60 Million	-1.77pp
2024-12-31	2.32%	CN¥60.26 Million ≈ $8.82 Million	CN¥2.60 Billion ≈ $380.77 Million	-1.32pp
2022-12-31	3.64%	CN¥100.06 Million ≈ $14.64 Million	CN¥2.75 Billion ≈ $402.59 Million	-11.20pp
2021-12-31	14.84%	CN¥360.84 Million ≈ $52.80 Million	CN¥2.43 Billion ≈ $355.81 Million	--

pp = percentage points

About Hangzhou Biotest Biotech Co Ltd

SHG:688767 China Biotechnology

Market Cap

$909.71 Million

CN¥6.22 Billion CNY

Market Cap Rank

#9420 Global

#2413 in China

Share Price

CN¥41.63

Change (1 day)

+12.51%

52-Week Range

CN¥30.56 - CN¥48.37

All Time High

CN¥125.45